Literature DB >> 30268099

High prevalence and clonal dissemination of OXA-72-producing Acinetobacter baumannii in a Chinese hospital: a cross sectional study.

Yong Chen1, Yuying Yang2,3, Lin Liu1,4, Guangbin Qiu5, Xuelin Han1, Shuguang Tian1, Jingya Zhao1, Fangyan Chen1, Hajo Grundmann6,7, Haifeng Li8, Jinke Sun9,10,11, Li Han12.   

Abstract

BACKGROUND: Carbapenem resistance in Acinetobacter baumannii in China was mainly mediated by OXA-23-like carbapenemases, while OXA-24/40-like carbapenemases were rarely identified. OXA-72 is one variant of OXA-24/40-like carbapenemases. This study aimed to demonstrate the epidemiology and characterizations of OXA-72-producing A. baumannii in a Chinese hospital.
METHODS: A total of 107 clinical A. calcoaceticus-A. baumannii (Acb) complex isolates were collected in a Chinese hospital during between 2014 and 2016. These isolates were identified using Vitek 2 system and gyrB multiplex PCR. Vitek 2 system was used for antibiotic susceptibility testing. Genes encoding for major classes of carbapenemases were investigated by PCR. Rep-PCR was used for genotyping of all the A. baumannii isolates. The risk factors for carriage of OXA-72-producing or OXA-23-producing A. baumannii were analyzed through univariate and multivariate logistic regression.
RESULTS: Of the 107 Acb isolates collected, 101 isolates (94.4%) and 6 isolates (5.6%) were identified as A. baumannii and A. pittii, respectively. 78 A. baumannii isolates (77.2%) were carbapenem resistant and mainly cultured from intensive care unit (ICU). blaOXA-72 and blaOXA-23 genes were identified in 45(57.7%) and 33(42.3%) carbapenem-resistant A. baumannii (CRAB), respectively. Multivariate risk factor analyses showed that prior carbapenem usage and nasogastric intubation were significantly associated with carriage of OXA-72-producing A. baumannii or OXA-23-producing A. baumannii. Rep-PCR analysis showed that 9 and 22 Rep-PCR types were assigned to 78 CRAB isolates and 23 carbapenem-susceptible A. baumannii (CSAB) isolates, respectively. A higher diverstiy of Rep-PCR patterns was observed among OXA-72-producing A. baumannii isolates than OXA-23-producing A. baumannii isolates, but all of them belonged to the same clone complex. MLST analysis suggested that the OXA-72 isolates from this study correspond to CC92/CC2 clone complex.
CONCLUSIONS: This study demonstrates high prevalence and potential clonal spread of closely related genotypes of OXA-72-producing A. baumannii within a Chinese hospital. Continuous surveillance is necessary to monitor the dissemination of these strains in other healthcare settings to guide infection control policies in order to curb the spread of this bacterium.

Entities:  

Keywords:  Acinetobacter baumannii; Clone dissemination; Molecular typing; OXA carbapenemases; Risk factor

Mesh:

Substances:

Year:  2018        PMID: 30268099      PMCID: PMC6162926          DOI: 10.1186/s12879-018-3359-3

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Acinetobacter is a gram-negative coccobacillus that has rapidly emerged as one of the most common nosocomial pathogens worldwide [1]. There are currently at least 31 described Acinetobacter genomic species [2], of which A. calcoaceticus, A. baumannii, A. pittii, and A. nosocomialis are very closely related, and difficult to distinguish from each other by phenotypic properties [3]. A. calcoaceticus-A. baumannii (Acb) complex has therefore been proposed to refer to these species [2]. Nevertheless, A. baumannii is the most clinically relevant and is notorious for its ability to accumulate diverse mechanisms of resistance [4, 5]. The carbapenem class of antibiotics is considered as the last-resort choice when treating Acinetobacter infections. However, an increasing prevalence of carbapenem resistance has been observed in clinical A. baumannii isolates from many parts of the world. Carbapenem-associated multiclass resistance among 55,330 U.S. A. baumannii isolates from The Surveillance Network database has increased from 20.6% in 2002 to 49.2% in 2008 [6]. In China, the resistance rate of clinical A. baumannii to carbapenem gradually increased from < 10% in 2000 to > 60% at present [7, 8]. The major mechanism of carbapenem resistance is production of OXA β-lactamases, which are clustered in three major groups, OXA-23-like, OXA-24/40-like, and OXA-58-like [9-11]. OXA-24/40 β-lactamase was first identified in A. baumannii from Spain in 1997 [12]. After that, A further 6 enzyme variants have since been discovered, including OXA-72 [11]. Unlike OXA-23-like, OXA-24/40 β-lactamases were less commonly identified in carbapenem resistant Acinetobacter spp. isolates [13]. A large surveillance of OXA-type β-lactamase gene clusters for a total of 2880 Acinetobacter spp. isolates collected from 23 Chinese provinces found that blaOXA-23-like and blaOXA-24/40-like genes were identified in 1316 isolates (45.7%) and 11 isolates (0.4%), respectively [14]. Therefore, OXA-24/40-like β-lactamases were only responsible for a small number of carbapenem-resistance isolates in China, their dissemination and epidemiology in healthcare settings deserves further surveillance and investigation. This study aimed to demonstrate the occurrence, clinical manifestation and genotypic characterizations of OXA-72-producing A. baumannii in a Chinese hospital.

Methods

Study settings and isolates information

A total of 107 clinical Acb complex isolates from 107 patients were collected at a tertiary-care comprehensive hospital in northeastern China with 1800 beds, from Oct 2014 to Oct 2016. These isolates were recovered from various specimens including sputum, blood, urine, pleural fluid, secretions and throat swab sample. For each patient, only a single colony of the first isolate was selected for subsequent analysis. All the clinical isolates were stored at − 80 °C until use. Data for each isolate and each patient were obtained through review of microbiology lab results and medical records. Risk factor data, including ICU stay, presence of invasive procedures and antibiotic treatment, referred to those which were present before the isolation of the index Acinetobacter strains. All data were anonymously collected and interpreted.

Strain identification and in vitro antibiotic susceptibility testing

Identification of Acb complex isolates was initially performed using automated identification systems the VITEK 2 compact system (BioMérieux, Craponne, France). Further identification of the Acb complex to the species level was performed by gyrB multiplex PCR [15, 16]. In vitro susceptibilities to ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, cefepime, meropenem, imipenem, gentamicin, amikacin, ciprofloxacin, levofloxacin, colistin, minocyline were determined by the VITEK 2 compact system (BioMérieux, Craponne, France). Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC 27853) were used as quality control strains. Results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI, 2016) guidelines.

Detection of carbapenemases genes

One white loop (1 μl) of 24 h plate culture of Acinetobacter bacteria was resuspended in 200 μl of sterilized and DNA free water. The bacterial suspensions were then heated for 10 min at 96 °C and centrifuged 5 min at 13000 rpm. The supernatant was used as the genomic DNA for the following molecular experiments. Genes encoding for major classes of A, B, and D carbapenemases for all the Acb isolates were investigated by PCR. The presence of blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, and blaOXA-58-like genes were detected through multiplex PCR assay [17]. Metallo-β-lactamase encoding genes, blaNDM-like, blaIMP-like and blaVIP-like, were detected with PCR conditions and primers as previously described [18]. The blaOXA-24-like variant was further identified through PCR and DNA sequencing as described [19].

Molecular typing

Rep-PCR was used for genotyping of all the A. baumannii isolates, using the primer pair REP 1(5’-IIIGCGCCGICAGGC-3′) and REP 2(5’-ACGTCTTATCAGGCCTAC-3′) [20]. The conditions for PCR and the gel electrophoresis were the same as previously described [21]. Rep-PCR results of each isolate was compared to all of the other isolates in a pairwise manner, isolates with identical band patterns were considered to be of identical Rep-PCR types. A minimum spanning tree was created to show the differences between patterns through BioNumerics 6.6 software (Applied Maths, Kortrijk, Belgium). The spanning tree was limited to those patterns that differ by a single band, two Rep-PCR types that differ by two or more bands were connected. Nine blaOXA-24-like gene positive representative isolates from each different Rep-PCR type were randomly chosen for multilocus sequence typing (MLST) analysis according to ‘Pasteur’ scheme [22].

A review of literature

Currently, there were two MLST schemes available for Acinetobacter. In order to differentiate between the two schemes, STs and CCs were designated as STB/CCB for the Bartual scheme and STP/CCP for the Pasteur scheme. A search of previous published papers giving the MLST results of OXA-24/40-like producing Acinetobacter spp. was conducted to illustrate the population structure of OXA-24/40 strains from different countries. The MLST data from ‘Pasteur’ scheme and ‘Bartual’ scheme were separately analyzed by Bionumerics 6.6 and presented as a minimum spanning tree for categorical data with default settings.

Statistical analysis

Statistical analyses were performed using SPSS 19.0 (IBM, Armonk, NY, USA). The comparisons of patients’ characterics were conducted by chi-square test or Mann-Whitney U test. The risk factors for carriage of blaOXA-72-positive or blaOXA-23-like-positive A. baumannii were analyzed through univariate and multivariate logistic regression. In multivariate logistic regression, ICU stay and length of ICU stay were not included as they were highly associated with many other predisposing factors, including invasive procedures and antibiotic use. The index of diversity and the 95% confidence intervals (CIs) were calculated as described previously [23]. P values < 0.05 are considered statistically significant.

Results

Of the 107 Acinetobacter isolates, 101 isolates (94.4%) and 6 isolates (5.6%) were identified as A. baumannii and A. pittii, respectively. Five A. pittii isolates were susceptible to all the antibiotics tested and one isolate exhibited an intermediate resistance phenotype to minocycline. Among the 101 A. baumannii isolates, 78 isolates (77.2%) were resistant to carbapenems (meropenem or imipenem). The rates of resistance to piperacilin/tazobactam, ampicillin/sulbactam, amikacin, gentamicin, ceftazidime, ciprofloxacin and levofloxacin in A. baumannii were all above 60%, as most of the carbapenem-resistance isolates exhibited a multidrug resistance phenotype. Four A. baumannii isolates were resistant to polymyxin. The 107 Acinetobacter isolates were cultured from 71 male and 46 female patients. Fifty-one isolates were cultured from patients in ICU and all these isolates were carbapenem-resistant. The detection of carbapenemase genes showed that 33 (42.3%) of the 78 carbapenem-resistant A. baumannii (CRAB) were positive for the blaOXA-23-like gene, while the other 45 isolates (57.7%) were positive for the blaOXA-24/40-like gene. All these isolates harboured blaOXA-51-like gene. DNA sequencing showed that all the blaOXA-24/40-like amplicons belonged to blaOXA-72 (GenBank accession number MF781069). The blaOXA-58-like gene was detected in one carbapenem-susceptible A. baumannii (CSAB) isolate, the MICs for imipenem and meropenem were 0.5 μg/ml and 0.25 μg/ml, respectively. None of these Acinetobacter isolates were positive for blaIMP-like, blaVIM-like or blaNDM-like genes. Eighty-four (83.2%) of 101 A. baumannii isolates were associated with an infection (primarily low respiratory tract infection) and antibiotic treatment, while the other 27 isolates were just colonized. The characterics of 101 patients colonized or infected with A. baumannii were shown in Table 1. There were no significant differences over age and gender distribution among patients colonized or infected with CRAB and CSAB strains. More than 60% of the CRAB patients stayed at ICU at the time of bacteria isolation, while only one CSAB patient stayed at ICU.
Table 1

Characteristics of 101 patients colonized or infected with Acinetobacter baumannii in a Chinese hospital

CharacteristicsNo. of patients colonized or infected with A. baumannii χ2P values
Carbapenem-resistant(n = 78)Carbapenem-susceptible(n = 23)
Age, median years(range)77(21,94)76(2,96)0.463
Male Gender, n(%)50(64.1)19(82.6)2.810.094
Length of hospital stay, median days (range)11(1,3650)8(1,1400)0.786
ICU stay, n (%)49(62.8)1(4.3)24.30< 0.001
Associated with an infection, n(%)67(85.9)17(73.9)1.070.302
All-cause mortality of patients 14 days after isolation of A. baumannii, n(%)16(20.5)4(17.4)0.0010.974

ICU intensive care unit

Characteristics of 101 patients colonized or infected with Acinetobacter baumannii in a Chinese hospital ICU intensive care unit The results of univariate logistic analysis showed that there were many common risk factors for carriage of OXA-72-producing A. baumannii or OXA-23-producing A. baumannii, such as ICU stay, mechanical ventilation, nasogastric intubation and carbapenem treatment (Table 2). In multivarite analysis, prior carbapenem usage and nasogastric intubation were significantly associated with carriage of OXA-72-producing A. baumannii or OXA-23-producing A. baumannii. An additional risk factor, urinary catheter, was also significantly associated with carriage of blaOXA-23-like-positive A. baumannii (Table 3).
Table 2

Univariate logistic analysis of risk factors for carriage of OXA-72-producing Acinetobacter baumannii or OXA-23-producing A. baumannii

CharacteristicsControl casesa(n = 23)OXA-72 cases(n = 45)OR(CI 95%)P valueOXA-23 cases(n = 33)OR(CI 95%)P value
Age, median(range)76(2,96)78(28,94)1.02(1.00,1.05)0.08178(21,90)1.00(0.99,1.03)0.460
Male gender, n(%)22(75.9)27(60.0)0.32(0.09,1.08)0.06723(69.7)0.48(0.13,1.79)0.484
ICU stay, n (%)1(4.3)27(60.0)33.00(4.08,267.04)0.00122(66.7)44.00(5.23,370.52)< 0.001
Length of stay in the ICU (days), median(range)0(0,2)5(0,100)2.29(1.20,4.37)0.0123(0,100)2.29(1.03,5.08)0.042
Predisposing factors
 Urinary catheter9(39.1)27(60.0)2.33(0.84,6.52)0.10623(69.7)3.58(1.17,10.96)0.026
 Mechanical ventilation2(8.7)18(40.0)7.00(1.46,33.59)0.01514(42.4)7.74(1.55,38.56)0.013
 Central venous catheter5(21.7)14(31.1)1.63(0.50,5.26)0.41717(51.5)3.83(1.15,12.74)0.029
 Tracheostomy1(4.3)10(22.2)6.29(0.75,52.56)0.09011(33.3)11.00(1.31,92.63)0.027
 Transfusion1(4.3)5(11.1)2.75(0.30,25.05)0.3697(21.2)5.92(0.68,51.92)0.108
 Nasogastric intubation4(17.4)28(62.2)7.82(2.27,26.91)0.00119(57.6)6.45(1.79,23.19)0.004
 Cephalosporin12(52.2)15(33.3)0.46(0.16,1.27)0.13612(36.4)0.53(0.17,1.55)0.242
 β-lactam/β-lactamase inhibitor combinations12(52.2)24(53.3)2.61(0.90,7.57)0.07712(36.4)1.31(0.42,4.07)0.645
 Quinolone3(13.0)19(42.2)4.87(1.26,18.79)0.02210(30.3)2.90(0.70,12.02)0.143
 Carbapenem4(17.4)21(46.7)4.16(1.22,14.18)0.02320(60.6)7.31(2.02,26.40)0.002

aControl cases: 23 patients colonized or infected with carbapenem-susceptible Acinetobacter baumannii

ICU intensive care unit

Table 3

Multivariate logistic analysis of risk factors for carriage of OXA-72-producing Acinetobacter baumannii or OXA-23-producing A. baumannii

CharacteristicsOXA-72 casesOXA-23 cases
OR(CI 95%)P valueOR(CI 95%)P value
Urinary catheter4.94(1.61–21.07)0.031
Nasogastric intubation7.65(2.14,27.36)0.0027.95(1.79–35.34)0.006
Carbapenem usage4.02(1.07,15.06)0.03910.05(2.21–45.58)0.003
Univariate logistic analysis of risk factors for carriage of OXA-72-producing Acinetobacter baumannii or OXA-23-producing A. baumannii aControl cases: 23 patients colonized or infected with carbapenem-susceptible Acinetobacter baumannii ICU intensive care unit Multivariate logistic analysis of risk factors for carriage of OXA-72-producing Acinetobacter baumannii or OXA-23-producing A. baumannii The results of Rep-PCR patterns and corresponding strain information for the 101 A. baumannii were shown in Table 4. In total, 9 Rep-PCR types were assigned to 78 CRAB isolates, while 22 Rep-PCR types were assigned to 23 CSAB isolates. The index of diversity (DI) for CRAB was 0.750 (95% CI: 0.671–0.829), which was significantly lower than for CSAB (DI = 0.996, 95% CI: 0.986–1.006). Twenty-six and 7 OXA-23-producing A. baumannii isolates were identified as Rep-PCR type 1 and 2, respectively, while 45 OXA-72-producing A. baumannii isolates were distributed in the 9 Rep-PCR types. Minimum spanning tree analysis of Rep-PCR patterns showed that all the 78 CRAB isolates were clustered into one clone complex, while most of the CSAB isolates were not connected to each other (Fig. 1). MLST analysis showed that all the 9 representative OXA-72 isolates in this study belong to ST2 (Table 4).
Table 4

The Rep-PCR type, MLST type, presence of carbapenemase genes and antimicrobial resistance profile of 101 Acinetobacter baumannii isolates

Isolate IDRep-PCR typeMLST typeCarbapenemase genesAntimicrobial resistance profile
IMPMEMCAZFEPAMKGENCIPLVXTZPSAMMHCOL
N13121NA bla OXA-23 RRRRRRRRRRSS
N13141NA bla OXA-23 RRRIRRRRRRSS
N13161NA bla OXA-23 RRRRRRRRRRSS
N13181NA bla OXA-23 RRRISRRRRISS
N13521NA bla OXA-23 RRRRRRRIRRSS
N13591NA bla OXA-23 RRRRRRRIRRSS
N13621NA bla OXA-23 RRRRRRRRRRSS
N13691NA bla OXA-23 RRRRRIRIRRSS
N13711NA bla OXA-23 RRRRRRRIRRSS
N13831NA bla OXA-23 RRRRRRRRRRSS
N13841NA bla OXA-23 RRRRRRRRRRSS
N13861NA bla OXA-23 RRRRRRRIRRSR
N13951NA bla OXA-23 RRRRRRRRRRSS
N13961NA bla OXA-23 RRRRRRRRRRSS
N13981NA bla OXA-23 IRRRRRRRRISS
N14011NA bla OXA-23 RRRRRRRRRISS
N14071NA bla OXA-23 RRRRRRRRRRSS
N7411NA bla OXA-23 RRRRRRRRRRSS
N7471NA bla OXA-23 RRRIRRRRRSIS
N7481NA bla OXA-23 RRRRRRRRSRIS
N7491NA bla OXA-23 RRRRRRRRRRSS
N7511NA bla OXA-23 RRRRRRRRRRSS
N7521NA bla OXA-23 RRRRRRRRRRIS
N7561NA bla OXA-23 RRRIRRRRRSSS
N7621NA bla OXA-23 RRRRRRRRRRIS
N7641NA bla OXA-23 RRRRRRRRRRIS
N13041NA bla OXA-72 RRRSRRRIRISS
N130712 bla OXA-72 RRRIRRRRRISS
N13091NA bla OXA-72 RRRRRRRIRRSS
N13111NA bla OXA-72 RRRIRRRIRISS
N13151NA bla OXA-72 RRRRRRRRRRSS
N7431NA bla OXA-72 RRRRRRRRRRRS
N7451NA bla OXA-72 RRRIRRRRRIIS
N7501NA bla OXA-72 RRRIRRRRRRIS
N7541NA bla OXA-72 RRRIRRRRRISS
N14122NA bla OXA-23 IRRRRRRRRRSS
N14192NA bla OXA-23 IRRRRRRRRRSS
N14202NA bla OXA-23 RRRRRRRRRSSS
N14242NA bla OXA-23 IRRRRRRRRRSS
N14282NA bla OXA-23 RRRRRRRRRISS
N14472NA bla OXA-23 RRRRRRRIRRSS
N14492NA bla OXA-23 RRRRRRRIRRSS
N13722NA bla OXA-72 RRRIRRRRRRIS
N14112NA bla OXA-72 RRRIRRRRRRSS
N142522 bla OXA-72 RRRSRRRRRISS
N14462NA bla OXA-72 RRRIRRRRRRSS
N14512NA bla OXA-72 RRRRRRRRRRIS
N13483NA bla OXA-72 RRRIRRRRRRSS
N13493NA bla OXA-72 RRRIRRRRRRSS
N13683NA bla OXA-72 RRRIRRRRRRSS
N13763NA bla OXA-72 RRRSRRRRRRSS
N13783NA bla OXA-72 RRRIRRRRRRSS
N142132 bla OXA-72 RRRIRRRRRISS
N14273NA bla OXA-72 RRRIRRRRRRSS
N14293NA bla OXA-72 RRRISSRIRRSS
N14323NA bla OXA-72 RRRIRRRRRSSS
N14363NA bla OXA-72 RRRRRRRRRRSS
N14373NA bla OXA-72 RRRIRRRRRRSS
N13654NA bla OXA-72 RRRIRRRRRRSS
N13664NA bla OXA-72 RRRRRRRRRRSS
N142242 bla OXA-72 RRRSRRRIRISS
N14344NA bla OXA-72 RRRIRRRRRRSS
N13615NA bla OXA-72 RRRIRRRRRRSS
N13755NA bla OXA-72 RRRRRIRRRRSS
N13805NA bla OXA-72 RRRSRRRRRRSS
N13815NA bla OXA-72 RRRSRRRRRRSS
N139752 bla OXA-72 RRRIRRRRRRSS
N14005NA bla OXA-72 RRRIRRRRRRSS
N13506NA bla OXA-72 RRRIRRRRRRSS
N135362 bla OXA-72 RRRRRRRRRRSS
N13706NA bla OXA-72 RRRIRRRRRRIS
N139172 bla OXA-72 RRRRRRRRRRSS
N135782 bla OXA-72 RRSSSRRRISSS
N13748NA bla OXA-72 RRRIRRRRRRSS
N13798NA bla OXA-72 RRRIRRRRRRSS
N13928NA bla OXA-72 RRRSRRRRRRSS
N14098NA bla OXA-72 RRRSRRRIRISS
N138292 bla OXA-72 RRRSRRRRRRSS
N141510NANoneSSSSSSSSSSSS
N144111NANoneSSSSSRSSSRSS
N144312NANoneSSSSSSSSSSSS
N140813NANoneSSSSSSSSSSSS
N130614NANoneSSSSSSSSSSSS
N141415NANoneSSSSSSSSSSSS
N136316NANoneSSSSSSSSSSSS
N138917NANoneSSSSSSSSSSSS
N140518NANoneSSSSSSSSSSSS
N140618NANoneSSSSSSSSSSSR
N137719NANoneSSRRRRRRRRSS
N139020NA bla OXA-58 SSSSSRSSSSSS
N144821NANoneSSSSSRRRSSSR
N135422NANoneSSSSSSSSSSSS
N74623NANoneSSSSSSSSSISS
N136424NANoneSSSSSSSSSSSS
N139325NANoneSSSSSSSSSSSS
N135126NANoneSSSSSSSSSSSS
N139927NANoneSSSSSSSSSSSS
N130528NANoneSSSSSSSSSSSS
N138729NANoneSSSSSSSSSSSS
N74430NANoneSSSSSSSSSSSR
N142331NANoneSSSSSSSSSSSS

NA not available, IMP imipenem, MEM meropenem, CAZ ceftazidime, FEP cefepime, AMK amikacin, GEN gentamicin, CIP ciprofloxacin, LVX levofloxacin, TZP piperacillin-tazobactam, SAM ampicillin-sulbactam, MH minocyline, COL colistin, R resistant, I intermediate, S susceptible

Fig. 1

Minimum spanning tree of 101 Acinetobacter baumannii isolates based on Rep-PCR patterns. Each circle represents one unique genotype. OXA-72-producing carbapenem-resistant A. baumannii (CRAB), OXA-23-producing CRAB and carbapenem-susceptible A. baumannii (CSAB) isolates are indicated with red, green, and blue colors, respectively. The size of each circle corresponds to the number of isolates. The lines connecting the circles indicate those patterns that differ by a single band. R: carbapenem-resistant strains. S: carbapenem-susceptible strains

The Rep-PCR type, MLST type, presence of carbapenemase genes and antimicrobial resistance profile of 101 Acinetobacter baumannii isolates NA not available, IMP imipenem, MEM meropenem, CAZ ceftazidime, FEP cefepime, AMK amikacin, GEN gentamicin, CIP ciprofloxacin, LVX levofloxacin, TZP piperacillin-tazobactam, SAM ampicillin-sulbactam, MH minocyline, COL colistin, R resistant, I intermediate, S susceptible Minimum spanning tree of 101 Acinetobacter baumannii isolates based on Rep-PCR patterns. Each circle represents one unique genotype. OXA-72-producing carbapenem-resistant A. baumannii (CRAB), OXA-23-producing CRAB and carbapenem-susceptible A. baumannii (CSAB) isolates are indicated with red, green, and blue colors, respectively. The size of each circle corresponds to the number of isolates. The lines connecting the circles indicate those patterns that differ by a single band. R: carbapenem-resistant strains. S: carbapenem-susceptible strains A literature review of previous published MLST data showed that there were at least 19 ST types (Bartual scheme) for 29 OXA-24/40-like producing Acinetobacter spp. isolates from 11 countries and 21 ST types (Pasteur scheme) for 52 OXA-24/40-like producing Acinetobacter spp. isolates from 15 countries. Minimum spanning tree analysis of these isolates based on two different MLST schemes was shown in Fig. 2, which suggested that CC92B/CC2P represented the predominant clone for the OXA-24/40-like producing Acinetobacter spp. isolates from around the world.
Fig. 2

Minimum spanning tree analysis of blaOXA-72-positive Acinetobacter baumannii isolates based on multilocus sequence typing (MLST) data from published literatures. The left panel (a) showed the results from ‘Bartual’ scheme, the right panel (b) showed the results from ‘Pasteur’ scheme. Each circle represents an independent sequence type (ST). The size of each circle corresponds to the number of isolates. The lines connecting the circles indicate the relationship between different STs. Black arrows are used to indicate the strains originated from China

Minimum spanning tree analysis of blaOXA-72-positive Acinetobacter baumannii isolates based on multilocus sequence typing (MLST) data from published literatures. The left panel (a) showed the results from ‘Bartual’ scheme, the right panel (b) showed the results from ‘Pasteur’ scheme. Each circle represents an independent sequence type (ST). The size of each circle corresponds to the number of isolates. The lines connecting the circles indicate the relationship between different STs. Black arrows are used to indicate the strains originated from China

Discussions

Carbapenem-resistant Acinetobacter spp. (mainly CRAB) are increasingly recognized as major nosocomial pathogens and considered to be serious threat for human health by US Centers for Disease Control and Prevention and World Health Organization [24, 25]. OXA-23-like carbapenemases were the main reason for the high prevalence and wide dissemination of CRAB from many parts of the world, including China [14, 26, 27]. OXA-24/40-like carbapenemases, which have been reported to be associated with outbreak of nosocomial infection in United States, Spain, Turkey and Ecuador [28-31], accounted for only a small part of CRAB in China [14, 32]. OXA-72, which was first identified in 2004 in an A. baumannii isolate from Thailand, belonged to one of the most important variant of OXA-24/40-like carbapenemases [29]. This study reported firstly a high prevalence and clonal dissemination of OXA-72-producing A. baumannii in a hospital from northeastern China. Carbapenem resistance in A. baumannii was not significantly associated with 14-day mortality in this study (Table 1), which is in accordance with previous studies [33, 34]. However, carbapenem resistance limits the available therapeutic agents, makes the infection difficult to treat, and might be associated with an additional cost of hospitalization [34]. In this study, there was no significant difference over length of hospital stay for carbapenem resistance and susceptible A. baumannii, which might be related with the limited sample size. In vitro antimicrobial susceptibility testing showed that OXA-72-producing A. baumannii and OXA-23-producing A. baumannii exhibited similar multidrug resistance profile, suggesting that they could not be differentiated through detection of antimicrobial phenotype. The risk factor analyses implicated that admitted into ICU and length of ICU stay were the most important risk factors for carriage of OXA-72-producing A. baumannii and OXA-23-producing A. baumannii, as ICU patients are always critical ill and subjected to a lot of risk factors for the acquisition of multidrug resistance organisms (MDROs) [35]. When ICU stay was removed for multivariable analyses, nasogastric intubation and carbapenem use were significantly associated with acquisition of both classes of CRAB, which is in accordance with previous studies [36-38]. The reason for why urinary catheter was significantly associated with carriage of OXA-23-producing A. baumannii, but not OXA-72-producing A. baumannii deserves further investigation. One possible explanation was that the complex conditions and combined therapy of ICU patients compromised the accuracy of multiple logistics analysis, urinary catheter might be just an indicator for critical ill patients who have a high probability of acquiring certain MDROs through contaminated environment or nursing behavior. CC92B/CC2P was by far the largest and most widely distributed A. baumannii clone in the world, especially among OXA-23-producing A. baumannii [27, 39, 40]. Although not so widely disseminated, CC92B/CC2P was still the most important clone in OXA-24/40-producing A. baumannii (Fig. 2). The Rep-PCR and MLST analysis of A. baumannii in this study suggested that OXA-72-producing and OXA-23-producing A. baumannii isolates were genetically related and belonged to the same clone, CC92B/CC2P. It seems that OXA-72-producing A. baumannii has already become endemic in the ICU since 2014, as most of these isolates were continuously cultured without obvious clustering of isolation time. Enhanced infection control measures, such as hand hygiene education programs, environmental cleaning, antimicrobial stewardship, contact precautions [41], have to be implemented in ICU of this hospital in order to reduce the wide spread of high risk clone, CC92B/CC2P, which represents the most prevalent clone of CRAB in Chinese hospitals. There are some limitations for this study. The first is the inclusion criteria of Acb complex strains, it has been demonstrated that a single patient may have more than one genetic type of Acinetobacter [42, 43]. To avoid the problem of duplicate data, this study adopted a simple inclusion method of allowing only a single isolate per patient. it might limit the ability to monitor the dynamic changes and complex conditions in patients who may be at particular risk of acquiring antibiotic resistant strains through cross-infection or the development of resistance during antibiotic treatment [44]. Another limitation comes from the design of this study, as this is just an one-center study, the epidemiological characterizations of OXA-72 strains in this study might not be generalized to other healthcare settings in China.

Conclusions

This study described firstly a high prevalence of OXA-72-producing A. baumannii in ICU of a Chinese hospital, which have circulated in this ICU through clonal dissemination for at least two years. Strict infection control measures must be implemented to contain the ongoing dissemination of OXA carbapenemases-producing A. baumannii in Chinese ICUs.
  44 in total

1.  Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms.

Authors:  H Grundmann; S Hori; G Tanner
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

Review 2.  Epidemiology and control of antibiotic resistance in the intensive care unit.

Authors:  Jean Carlet; Adel Ben Ali; Annie Chalfine
Journal:  Curr Opin Infect Dis       Date:  2004-08       Impact factor: 4.915

3.  Patients with Acinetobacter baumannii bloodstream infections are colonized in the gastrointestinal tract with identical strains.

Authors:  Kerri A Thom; William W L Hsiao; Anthony D Harris; O Colin Stine; David A Rasko; J Kristie Johnson
Journal:  Am J Infect Control       Date:  2010-06-08       Impact factor: 2.918

4.  OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.

Authors:  G Bou; A Oliver; J Martínez-Beltrán
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 5.  ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients.

Authors:  E Tacconelli; M A Cataldo; S J Dancer; G De Angelis; M Falcone; U Frank; G Kahlmeter; A Pan; N Petrosillo; J Rodríguez-Baño; N Singh; M Venditti; D S Yokoe; B Cookson
Journal:  Clin Microbiol Infect       Date:  2014-01       Impact factor: 8.067

6.  Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program.

Authors:  Rodrigo E Mendes; Jan M Bell; John D Turnidge; Mariana Castanheira; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2008-10-27       Impact factor: 5.790

Review 7.  Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii.

Authors:  Nabil Karah; Arnfinn Sundsfjord; Kevin Towner; Ørjan Samuelsen
Journal:  Drug Resist Updat       Date:  2012-07-27       Impact factor: 18.500

8.  Class D β-lactamases: are they all carbapenemases?

Authors:  Nuno T Antunes; Toni L Lamoureaux; Marta Toth; Nichole K Stewart; Hilary Frase; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

9.  The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool.

Authors:  Laure Diancourt; Virginie Passet; Alexandr Nemec; Lenie Dijkshoorn; Sylvain Brisse
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

10.  Wide distribution of CC92 carbapenem-resistant and OXA-23-producing Acinetobacter baumannii in multiple provinces of China.

Authors:  Zhi Ruan; Yan Chen; Yan Jiang; Hua Zhou; Zhihui Zhou; Ying Fu; Haiping Wang; Yanfei Wang; Yunsong Yu
Journal:  Int J Antimicrob Agents       Date:  2013-08-09       Impact factor: 5.283

View more
  8 in total

1.  Acinetobacter baumannii Sequence Types Harboring Genes Encoding Aminoglycoside Modifying Enzymes and 16SrRNA Methylase; a Multicenter Study from Pakistan.

Authors:  Mohsin Khurshid; Muhammad Hidayat Rasool; Usman Ali Ashfaq; Bilal Aslam; Muhammad Waseem; Muhammad Akhtar Ali; Ahmad Almatroudi; Farhan Rasheed; Muhammad Saeed; Qinglan Guo; Minggui Wang
Journal:  Infect Drug Resist       Date:  2020-08-18       Impact factor: 4.003

2.  Characterization of a small plasmid carrying the carbapenem resistance gene bla OXA-72 from community-acquired Acinetobacter baumannii sequence type 880 in China.

Authors:  Huiqiong Jia; Qingyang Sun; Zhi Ruan; Xinyou Xie
Journal:  Infect Drug Resist       Date:  2019-06-06       Impact factor: 4.003

3.  Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii.

Authors:  Mohammad Hamidian; Steven J Nigro
Journal:  Microb Genom       Date:  2019-10

4.  Predominance of international clone 2 multidrug-resistant Acinetobacter baumannii clinical isolates in Thailand: a nationwide study.

Authors:  Piyatip Khuntayaporn; Pohnvipa Kanathum; Jantana Houngsaitong; Preecha Montakantikul; Krit Thirapanmethee; Mullika Traidej Chomnawang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-03-20       Impact factor: 3.944

Review 5.  Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals.

Authors:  Susan Ibrahim; Nadal Al-Saryi; Israa M S Al-Kadmy; Sarah Naji Aziz
Journal:  Mol Biol Rep       Date:  2021-08-30       Impact factor: 2.316

6.  Molecular epidemiology and carbapenem resistance characteristics of Acinetobacter baumannii causing bloodstream infection from 2009 to 2018 in northwest China.

Authors:  Yihai Gu; Wei Zhang; Jine Lei; Lixia Zhang; Xuan Hou; Junqi Tao; Hui Wang; Minghui Deng; Mengrong Zhou; Rui Weng; Jiru Xu
Journal:  Front Microbiol       Date:  2022-08-22       Impact factor: 6.064

7.  Whole-Genome-Sequence-Based Characterization of Extensively Drug-Resistant Acinetobacter baumannii Hospital Outbreak.

Authors:  Ghiwa Makke; Ibrahim Bitar; Tamara Salloum; Balig Panossian; Sahar Alousi; Harout Arabaghian; Matej Medvecky; Jaroslav Hrabak; Samar Merheb-Ghoussoub; Sima Tokajian
Journal:  mSphere       Date:  2020-01-15       Impact factor: 4.389

8.  Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.

Authors:  Mariana Neri Lucas Kurihara; Romário Oliveira de Sales; Késia Esther da Silva; Wirlaine Glauce Maciel; Simone Simionatto
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-06       Impact factor: 1.581

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.